CA3219597A1 - Novel process - Google Patents

Novel process Download PDF

Info

Publication number
CA3219597A1
CA3219597A1 CA3219597A CA3219597A CA3219597A1 CA 3219597 A1 CA3219597 A1 CA 3219597A1 CA 3219597 A CA3219597 A CA 3219597A CA 3219597 A CA3219597 A CA 3219597A CA 3219597 A1 CA3219597 A1 CA 3219597A1
Authority
CA
Canada
Prior art keywords
group
typically
piperidine
solvent
protected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219597A
Other languages
English (en)
French (fr)
Inventor
Paul Fraser
Jetta PALGUNA
Mallesh BHARATHA
Josephine Eliette Francoise Cinqualbre
Regis Jean Georges Mondiere
Paolo TOSATTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA3219597A1 publication Critical patent/CA3219597A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3219597A 2021-06-23 2022-06-23 Novel process Pending CA3219597A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202141028180 2021-06-23
IN202141028180 2021-06-23
PCT/EP2022/067126 WO2022268935A2 (en) 2021-06-23 2022-06-23 Novel process

Publications (1)

Publication Number Publication Date
CA3219597A1 true CA3219597A1 (en) 2022-12-29

Family

ID=82458485

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3219597A Pending CA3219597A1 (en) 2021-06-23 2022-06-23 Novel process

Country Status (12)

Country Link
US (1) US20240150291A1 (https=)
EP (1) EP4359385A2 (https=)
JP (1) JP2024524215A (https=)
KR (1) KR20240024842A (https=)
CN (1) CN118019727A (https=)
AR (1) AR126215A1 (https=)
AU (1) AU2022300325A1 (https=)
CA (1) CA3219597A1 (https=)
IL (1) IL308071A (https=)
MX (1) MX2023014547A (https=)
TW (1) TW202317514A (https=)
WO (1) WO2022268935A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128498A1 (es) * 2022-02-15 2024-05-15 Hoffmann La Roche Procesos novedosos
WO2024133610A1 (en) * 2022-12-23 2024-06-27 F. Hoffmann-La Roche Ag Proccesses for the preparation of an nlrp3 inhibitor
IL325043A (en) 2023-08-16 2026-01-01 Hoffmann La Roche Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69727837T2 (de) * 1997-05-02 2004-12-30 Dr. Reddy's Research Foundation, Hyderabad Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
HUP0303204A3 (en) * 2000-11-16 2010-04-28 Sankyo Co 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
US7220735B2 (en) * 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists
TW200524865A (en) * 2003-10-08 2005-08-01 Nicholas Piramal India Ltd Fibrinogen receptor antagonists and their use
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
JP5508027B2 (ja) * 2007-02-22 2014-05-28 メルク セローノ ソシエテ アノニム キノキサリン化合物及びその使用
JP5898962B2 (ja) * 2012-01-11 2016-04-06 東京応化工業株式会社 レジスト組成物及びレジストパターン形成方法
WO2017095758A1 (en) * 2015-12-01 2017-06-08 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use
US11465992B2 (en) * 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
EP3668861A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3773576A4 (en) * 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CR20200588A (es) * 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
CA3113573A1 (en) * 2018-09-21 2020-03-26 Novartis Ag Isoxazole carboxamide compounds and uses thereof
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
WO2022268935A3 (en) 2023-02-02
IL308071A (en) 2023-12-01
TW202317514A (zh) 2023-05-01
EP4359385A2 (en) 2024-05-01
US20240150291A1 (en) 2024-05-09
CN118019727A (zh) 2024-05-10
AR126215A1 (es) 2023-09-27
KR20240024842A (ko) 2024-02-26
AU2022300325A8 (en) 2023-11-16
AU2022300325A1 (en) 2023-11-02
WO2022268935A2 (en) 2022-12-29
JP2024524215A (ja) 2024-07-05
MX2023014547A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
CA3219597A1 (en) Novel process
DK2593429T3 (en) A process for preparing a biphenyl-2-ylcarbamic acid
ES2603028T3 (es) Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos
KR20200057705A (ko) 리보시클립 및 그의 염의 제조를 위한 개선된 방법
AU2018205994B2 (en) Process for the preparation of 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
CN106220624B (zh) 制备阿哌沙班n-1形式的方法
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
US20240400516A1 (en) Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivataives
AU2021374232A1 (en) Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
EP4638422A1 (en) Proccesses for the preparation of an nlrp3 inhibitor
CN117304253A (zh) 一种二氮杂双环拟肽衍生物的制备方法及应用
HK40105889A (zh) 用於制备nlrp3抑制剂的方法
ES2912409T3 (es) Intermedios y procesos para la preparación de linagliptina y sus sales
CN101781299B (zh) 一种喹诺酮类药物关键中间体的一锅法合成方法
CN118234729A (zh) 用于制备双环甘氨酸-脯氨酸化合物和其单环甘氨酸-脯氨酸中间体的方法
WO2025240465A1 (en) Processes for preparing macrocyclic compounds
CN121202865A (zh) 非唑奈坦及其中间体的制备方法和中间体
BR112019013884B1 (pt) Processo para a preparação de compostos de 5 -amino -6h´ -tiazolo [4,5 -d] pirimidina -2,7 -diona 3 -substituídos

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240927

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250526

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250526